Phase 2/3: ?Double-Blind, Randomized, Placebo Controlled, Safety and Efficacy Trial of BHV-3000 (rimegepant) Orally Disintegrating Tablet (ODT) for the Acute Treatment of Temporomandibular Disorders (TMD)

Project: Research project

Project Details

Description

Phase 2/3: ?Double-Blind, Randomized, Placebo Controlled, Safety and Efficacy Trial of BHV-3000 (rimegepant) Orally Disintegrating Tablet (ODT) for the Acute Treatment of Temporomandibular Disorders (TMD)
StatusActive
Effective start/end date1/1/228/31/23

Funding

  • BIOHAVEN PHARMACEUTICALS LLC

Fingerprint

Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.